You just read:

Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

News provided by

Soligenix, Inc.

Jul 27, 2017, 07:23 ET